Liquidia Corporation

Healthcare · Drug Manufacturers - Specialty & Generic · United States

Last price 44.99 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 4.03B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company’s lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L6...